-The Economic Times Extension of life is priceless. Simply priceless." These were the words of Venkat Krishnan (name changed) to Novartis after receiving treatment with Glivec for about two years. Following his diagnosis with chronic myeloid leukaemia (CML), Venkat married his college sweetheart against the wishes of her family. After all, the prognosis in those days for people suffering from CML was not promising. Taking interferon, a powerful immune therapy, was the...

-Live Mint SC judgement may not open a floodgate of revenues for local pharma firms; nevertheless, it is a psychological win The Supreme Court has dismissed an appeal by Novartis AG to revoke denial of a patent to its cancer drug Glivec. The judgement is important because multinational companies (MNCs) can be denied patent protection on improved drugs unless they can prove the medication has better efficacy. Although this decision will displease...

-World Bank Blog The enormity of the global job-creation challenge is underscored in a comprehensive new analysis by the International Finance Corporation, which issued a wide-ranging Jobs Study at a recent IFC forum  on the urgency of the unemployment crisis. More than 200 million people are now unemployed worldwide – with another 1.5 billion people only marginally employed, and with an additional 2 billion working-age adults neither working nor seeking a...

-The Economic Times Pharmaceutical multinationals have begun using the Right to Information law to launch pre-emptive legal action against local generic players to protect the market of patented drugs and delay the entry of low cost generic medicines in the 60,000-crore domestic drug market. MNCs are using such information to sue generic firms even at a stage when their marketing approval is still pending or during the few months' window between the...

-Live Mint There are also ways in which we can help Indian institutions that have come to us seeking access to our technologies Bangalore: A key perception change is emerging in the global pharmaceutical industry on the long-established divide between the so-called generics and innovative business. While the two are still at loggerheads in several developed as well as developing markets, the world’s top drugmakers are reinventing the wheel. Paris-based Sanofi SA,...